ArticleInternational journal of general medicine2025
Effect of Recombinant Human Brain Natriuretic Peptide Therapy After PCI in Patients with Acute Myocardial Infarction and Its Impact on Cardiac Function: A Retrospective Controlled Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the efficacy of recombinant human brain natriuretic peptide (rhBNP) therapy after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) and its impact on cardiac function. Methods: In this retrospective controlled study, 104 AMI patients who underwent PCI at our hospital between September 2021 and December 2024 were consecutively enrolled and assigned to groups based on the treatment period. The control group (n=52) (patients admitted from September 2021 to December 2022) received standard guideline-directed medical therapy (GDMT), while the observation group (n=52) (patients admitted from January 2023 to December 2024) received additional intravenous rhBNP treatment for 72 hours on top of GDMT. The therapeutic effects, cardiac ultrasound parameters (LVEF, LVEDD, LVESD, FS), key myocardial injury markers (CK-MB, cTnI), inflammatory markers (IL-6, TNF-α, Hcy), and major adverse cardiovascular events (MACE) incidence were compared. Multivariate regression analyses were performed to adjust for potential baseline confounders. Results: The observation group demonstrated a significantly higher overall efficacy than the control group (94.23% vs 78.85%, P<0.05). Post-treatment, both groups showed significant improvements in LVEF, FS, LVESD, and reductions in CK-MB, cTnI, IL-6, TNF-α, and Hcy, with the observation group exhibiting more pronounced benefits (P<0.05). The between-group differences remained significant after adjusting for baseline characteristics. The incidence of MACE during the 6-month follow-up was significantly lower in the observation group (5.77% vs 19.23%, P<0.05). Conclusion: Adjunctive rhBNP therapy after PCI in AMI patients provides significant clinical benefits, including enhanced improvement of cardiac function, reduced myocardial injury and inflammatory stress, and a lower risk of MACE. However, these findings should be interpreted considering the study's limitations, including its retrospective design and single-center nature. Future prospective randomized trials are warranted for confirmation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.